News | Oncology Diagnostics | April 05, 2018

Myriad Receives Pre-Market Approval for BRACAnalysis Diagnostic System in Japan

Indicated as a companion diagnostic for Lynparza (olaparib) for use in patients with metastatic inoperable or recurrent breast cancer

April 5, 2018 — Myriad Genetic Laboratories Inc. announced that the Japanese Ministry of Health, Labour and Welfare has granted manufacturing and marketing approval for Myriad’s BRACAnalysis Diagnostic System to be used as a companion diagnostic with the PARP inhibitor, Lynparza.  Lynparza is marketed by AstraZeneca and Merck, known as MSD outside the United States and Canada.

AstraZeneca and Merck are seeking approval of Lynparza in Japan for treating patients with BRCA-mutated metastatic breast cancer. BRACAnalysis is the first and only diagnostic test for a PARP inhibitor to receive regulatory approval in Japan. The test is marketed in the United States as BRCAnalysis CDx.

Currently there are about 40,000 patients with metastatic disease that would be eligible for BRACAnalysis testing in Japan, with an estimated 15,000 new cases of HER2-negative breast cancer diagnosed each year. Myriad will commercialize BRACAnalysis in exclusive partnership with the SRL Inc., a subsidiary of Miraca Group, and one of the largest laboratory service providers in Japan.

BRACAnalysis is a diagnostic system that classifies a patient’s clinically significant variants (DNA sequence variations) in the BRCA1 and BRCA2 genes. Variants are classified into one of the five categories — “Deleterious,” “Suspected Deleterious,” “Variant of Uncertain Significance,” “Favor Polymorphism” or “Polymorphism.” Once the classification is completed, the results are sent to medical personnel in Japan for determining the eligibility of patients for treatment with Lynparza.

BRACAnalysis CDx was approved by the U.S. Food and Drug Administration (FDA) in December 2014 for patients with advanced ovarian cancer, and again in January 2018 for patients with HER2-negative metastatic breast cancer.

For more information: www.myriad.com

 

Related Content

AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of pol

a Schematic of the system. The entire solid tumour is illuminated from four sides by a four-arm fibre bundle. A cylindrically focused linear array is designed to detect optoacoustic signals from the tumour. In vivo imaging is performed in conical scanning geometry by controlling the rotation and translation stages. The sensing part of the transducer array and the tumour are submerged in water to provide acoustic coupling. b Maximum intensity projections of the optoacoustic reconstruction of a phantom of polyethylene microspheres (diameter, 20 μm) dispersed in agar. The inset shows a zoomed-in view of the region boxed with a yellow dashed line. In addition, the yellow boxes are signal profiles along the xy and z axes across the microsphere centre, as well as the corresponding full width at half-maximum values. c Normalized absorption spectra of Hb, HbO2 and gold nanoparticles (AuNPs). The spectrum for the AuNPs was obtained using a USB4000 spectrometer (Ocean Optics, Dunedin, FL, USA), while the spectra for Hb and HbO2 were taken from http://omlc.org/spectra/haemoglobin/index.html. The vertical dashed lines indicate the five wavelengths used to stimulate the three absorbers: 710, 750, 780, 810 and 850 nm. Optoacoustic signals were filtered into a low-frequency band (red) and high-frequency band (green), which were used to reconstruct separate images.

News | Breast Imaging | May 26, 2020
May 26, 2020 — Breast cancer is the most common cancer in women.
Phone call and linkage-to-care-based intervention increases mammography uptake among primary care patients at an urban safety-net hospital

Getty Images

News | Mammography | May 22, 2020
May 22, 2020 — Telephone outreach coupled with scheduling assistance significantly increased...
The Breast Imaging and Reporting System (BI-RADS) was established by the American College of Radiology to help classify findings on mammography. Findings are classified based on the risk of breast cancer, with a BI-RADS 2 lesion being benign, or not cancerous, and BI-RADS 6 representing a lesion that is biopsy-proven to be malignant.

Getty Images

News | Breast Imaging | May 19, 2020
May 19, 2020 — Women with mammographically detected breast lesions that are probably benign should have follow-up sur
Podcast: Impact of COVID-19 on Breast Cancer Treatment with Dr. Andrea Madrigrano

Kubtec hosts a Podcast: Impact of COVID-19 on Breast Cancer Treatment with Andrea Madrigrano, M.D., as part of its public service campaign.

News | Coronavirus (COVID-19) | May 06, 2020
May 6, 2020 — The COVID-19 pandemic is an unprec
The American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Cancer Network (NCCN), the Commission on Cancer (CoC) of the American College of Surgeons, and the American College of Radiology (ACR) have released new joint recommendations for prioritization, treatment and triage of breast cancer patients during the coronavirus (COVID-19) pandemic

Getty Images

News | Breast Imaging | April 13, 2020
April 13, 2020 — The American Society of Breast Surgeons (...
Table 1. Compared to 2-D mammography, which yields four images per patient, digital breast tomosynthesis (DBT), or 3-D mammography, produces hundreds of images per patient. While this provides more information for clinicians, the exponential increase in data can result in reader fatigue and burnout, which may ultimately affect patient care.

Table 1. Compared to 2-D mammography, which yields four images per patient, digital breast tomosynthesis (DBT), or 3-D mammography, produces hundreds of images per patient. While this provides more information for clinicians, the exponential increase in data can result in reader fatigue and burnout, which may ultimately affect patient care.

Sponsored Content | Case Study | Artificial Intelligence | April 09, 2020
As the largest independent imaging group in Michigan with 10 locations across the state,...
Figure 1. R MLO view from four different years. The skin mole is marked with a circular skin marker (TomoSPOT REF# 782, Beekley Medical) on the far-left image. These images demonstrate the potential for significant variability in location of the skin lesion due to movability of the skin during positioning.

Figure 1. R MLO view from four different years. The skin mole is marked with a circular skin marker (TomoSPOT REF# 782, Beekley Medical) on the far-left image. These images demonstrate the potential for significant variability in location of the skin lesion due to movability of the skin during positioning. 

Sponsored Content | Case Study | Breast Imaging | April 09, 2020
Christina Jacobs, M.D., Director of Breast Imaging (...
A recent study earlier this year in the journal Nature, which included researchers from Google Health London, demonstrated that artificial intelligence (AI) technology outperformed radiologists in diagnosing breast cancer on mammograms
Feature | Breast Imaging | April 06, 2020 | By Samir Parikh
A recent study earlier this year in the journal Nature,